[2025-05-13T17:05:58.300+0000] {local_task_job_runner.py:123} INFO - ::group::Pre task execution logs
[2025-05-13T17:05:58.316+0000] {taskinstance.py:2613} INFO - Dependencies all met for dep_context=non-requeueable deps ti=<TaskInstance: sec_filing_scheduler.process_alny manual__2025-05-13T17:05:43.854334+00:00 [queued]>
[2025-05-13T17:05:58.325+0000] {taskinstance.py:2613} INFO - Dependencies all met for dep_context=requeueable deps ti=<TaskInstance: sec_filing_scheduler.process_alny manual__2025-05-13T17:05:43.854334+00:00 [queued]>
[2025-05-13T17:05:58.326+0000] {taskinstance.py:2866} INFO - Starting attempt 1 of 1
[2025-05-13T17:05:58.343+0000] {taskinstance.py:2889} INFO - Executing <Task(PythonOperator): process_alny> on 2025-05-13 17:05:43.854334+00:00
[2025-05-13T17:05:58.368+0000] {warnings.py:112} WARNING - /home/***/.local/lib/python3.12/site-packages/***/task/task_runner/standard_task_runner.py:70: DeprecationWarning: This process (pid=981) is multi-threaded, use of fork() may lead to deadlocks in the child.
  pid = os.fork()

[2025-05-13T17:05:58.370+0000] {standard_task_runner.py:72} INFO - Started process 989 to run task
[2025-05-13T17:05:58.370+0000] {standard_task_runner.py:104} INFO - Running: ['***', 'tasks', 'run', 'sec_filing_scheduler', 'process_alny', 'manual__2025-05-13T17:05:43.854334+00:00', '--job-id', '98', '--raw', '--subdir', 'DAGS_FOLDER/orchestrate_clinical_pipeline.py', '--cfg-path', '/tmp/tmpkrfrdz2k']
[2025-05-13T17:05:58.374+0000] {standard_task_runner.py:105} INFO - Job 98: Subtask process_alny
[2025-05-13T17:05:58.454+0000] {task_command.py:467} INFO - Running <TaskInstance: sec_filing_scheduler.process_alny manual__2025-05-13T17:05:43.854334+00:00 [running]> on host c1a7243cf3b7
[2025-05-13T17:05:58.645+0000] {taskinstance.py:3132} INFO - Exporting env vars: AIRFLOW_CTX_DAG_OWNER='***' AIRFLOW_CTX_DAG_ID='sec_filing_scheduler' AIRFLOW_CTX_TASK_ID='process_alny' AIRFLOW_CTX_EXECUTION_DATE='2025-05-13T17:05:43.854334+00:00' AIRFLOW_CTX_TRY_NUMBER='1' AIRFLOW_CTX_DAG_RUN_ID='manual__2025-05-13T17:05:43.854334+00:00'
[2025-05-13T17:05:58.646+0000] {taskinstance.py:731} INFO - ::endgroup::
[2025-05-13T17:05:58.759+0000] {connection.py:277} WARNING - Connection schemes (type: google_cloud_platform) shall not contain '_' according to RFC3986.
[2025-05-13T17:05:58.761+0000] {base.py:84} INFO - Retrieving connection 'google_cloud_default'
[2025-05-13T17:05:59.955+0000] {logging_mixin.py:190} INFO - Found 141 8-K filings
[2025-05-13T17:05:59.956+0000] {logging_mixin.py:190} INFO - Found 13 10-K filings
[2025-05-13T17:05:59.956+0000] {logging_mixin.py:190} INFO - Found 37 10-Q filings
[2025-05-13T17:05:59.958+0000] {logging_mixin.py:190} INFO - Found 191 new filings.
[2025-05-13T17:05:59.959+0000] {logging_mixin.py:190} INFO - Processing 1 filings...
[2025-05-13T17:05:59.961+0000] {logging_mixin.py:190} INFO - Processing filing: 0001178670-25-000052
[2025-05-13T17:06:04.676+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:06:14.314+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:06:17.651+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:06:24.814+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:06:26.730+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:06:27.215+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:06:33.767+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:06:39.305+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:06:43.950+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:06:51.209+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:06:51.733+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:06:52.226+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:06:52.711+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:06:53.238+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:06:58.913+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:07:02.010+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:07:12.645+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:07:13.234+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:07:13.881+0000] {_client.py:1025} INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
[2025-05-13T17:07:14.631+0000] {logging_mixin.py:190} INFO - Uploaded 10-Q filing to GCS: gs://clinical_data_may25/ALNY/10-Q/2025/ALNY_10-Q_2025-05-01_0001178670-25-000052.txt
[2025-05-13T17:07:15.101+0000] {logging_mixin.py:190} INFO - Finished processing: 0001178670-25-000052
[2025-05-13T17:07:15.103+0000] {logging_mixin.py:190} INFO - 594 {'programs': [{'name': 'AMVUTTRA', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR amyloidosis with cardiomyopathy', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['ITEM 1A. RISK FACTORS', 'FILING DATE: 2025-05-01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867025000052/alny-20250331.htm'], 'aliases': []}, {'name': 'AMVUTTRA', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR amyloidosis with cardiomyopathy', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Launch in additional countries during the remainder of 2025'], 'references': ['SEC Filing', 'March 31, 2025'], 'aliases': []}, {'name': 'Leqvio', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC Filing', 'March 31, 2025'], 'aliases': []}, {'name': 'Qfitlia', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC Filing', 'March 31, 2025'], 'aliases': []}, {'name': 'zilebesiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC Filing', 'March 31, 2025'], 'aliases': []}, {'name': 'ONPATTRO', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC Filing', 'March 31, 2025'], 'aliases': []}, {'name': 'GIVLAARI', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC Filing', 'March 31, 2025'], 'aliases': []}, {'name': 'OXLUMO', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC Filing', 'March 31, 2025'], 'aliases': []}, {'name': 'Leqvio', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing', 'December 2021', ''], 'aliases': []}, {'name': 'Qfitlia', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing', '', ''], 'aliases': []}, {'name': 'zilebesiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing', '', ''], 'aliases': []}, {'name': 'mivelsiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': ['Ongoing Phase 2 development program'], 'upcoming_milestones': ["Full development and commercialization rights following Regeneron's opt-out"], 'references': ['SEC filing section 42', 'Filing date not specified', 'URL not available'], 'aliases': []}, {'name': 'zilebesiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': ["Phase 3 clinical trial initiation contingent on Roche's decision"], 'upcoming_milestones': ['Potential Phase 3 initiation milestone payment from Roche'], 'references': ['SEC filing section 42', 'Filing date not specified', 'URL not available'], 'aliases': []}, {'name': 'inclisiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Termination rights granted to Novartis with prior notice'], 'references': ['SEC filing section 42', 'Filing date not specified', 'URL not available'], 'aliases': []}, {'name': 'vutrisiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['NDA submission amendment due to third-party facility inspection'], 'references': ['SEC filing section 42', 'Filing date not specified', 'URL not available'], 'aliases': []}, {'name': 'AMVUTTRA', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR amyloidosis with cardiomyopathy', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'nucresiran', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR amyloidosis with cardiomyopathy', 'preclinical_data': [], 'clinical_trials': ['Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Patient enrollment for Phase 3 trial', 'Readouts and regulatory events dependent on enrollment'], 'references': [], 'aliases': ['formerly ALN-TTRsc04']}, {'name': 'mivelsiran', 'mechanism_of_action': '', 'target': '', 'indication': 'Alzheimer’s Disease', 'preclinical_data': [], 'clinical_trials': ['Phase 1 trial, partial clinical hold in the United States, results not specified'], 'upcoming_milestones': ['Potential impact of partial clinical hold on development plans'], 'references': [], 'aliases': []}, {'name': 'AMVUTTRA', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR-CM', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Expansion of indication approval outside the U.S.'], 'references': ['SEC filing', '2025'], 'aliases': []}, {'name': 'patisiran', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR amyloidosis with cardiomyopathy', 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 clinical trial', 'Patients with ATTR amyloidosis with cardiomyopathy', 'Results reported positive, but FDA issued a CRL in October 2023'], 'upcoming_milestones': [], 'references': ['SEC filing', '2023'], 'aliases': []}, {'name': 'inclisiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': ['NDA resubmission to the FDA filed in July 2021', 'FDA approved Leqvio in December 2021'], 'upcoming_milestones': [], 'references': ['SEC filing', '2021'], 'aliases': ['Leqvio']}, {'name': 'patisiran', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR amyloidosis with cardiomyopathy', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'vutrisiran', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR amyloidosis with cardiomyopathy', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'AMVUTTRA', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'AMVUTTRA', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR amyloidosis with cardiomyopathy', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'ONPATTRO', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'GIVLAARI', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'OXLUMO', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'vutrisiran', 'mechanism_of_action': '', 'target': '', 'indication': 'Stargardt Disease', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'Qfitlia', 'mechanism_of_action': '', 'target': '', 'indication': 'hemophilia', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'zilebesiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'fitusiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'AMVUTTRA', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'ONPATTRO', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'GIVLAARI', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'OXLUMO', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'AMVUTTRA', 'mechanism_of_action': 'RNAi therapeutic', 'target': '', 'indication': 'ATTR amyloidosis', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'AMVUTTRA', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR amyloidosis with cardiomyopathy', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'WAINUA', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR amyloidosis with cardiomyopathy', 'preclinical_data': [], 'clinical_trials': ['Phase 3'], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, {'name': 'nexiguran ziclumeran', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR amyloidosis with cardiomyopathy', 'preclinical_data': [], 'clinical_trials': ['Phase 3'], 'upcoming_milestones': [], 'references': [], 'aliases': ['formerly NTLA-2001']}, {'name': 'ALN-2220', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR amyloidosis with cardiomyopathy', 'preclinical_data': [], 'clinical_trials': ['Phase 3'], 'upcoming_milestones': [], 'references': [], 'aliases': ['formerly NI006']}, {'name': 'coramitug', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': ['Phase 2'], 'upcoming_milestones': [], 'references': [], 'aliases': ['NNC-6019-0001']}, {'name': 'ATO-02', 'mechanism_of_action': '', 'target': '', 'indication': 'hATTR amyloidosis with polyneuropathy', 'preclinical_data': [], 'clinical_trials': ['Phase 2'], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'RIVFLOZA', 'mechanism_of_action': '', 'target': '', 'indication': 'PH1', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'OXLUMO', 'mechanism_of_action': 'RNAi therapeutic', 'target': '', 'indication': 'PH1', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'TEGSEDI', 'mechanism_of_action': 'antisense drug', 'target': '', 'indication': 'hATTR amyloidosis with polyneuropathy', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}]}
[2025-05-13T17:07:15.108+0000] {logging_mixin.py:190} INFO - Finished 1/1: 0001178670-25-000052
[2025-05-13T17:07:15.112+0000] {logging_mixin.py:190} INFO - 609 {'programs': [{'name': 'AMVUTTRA', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR amyloidosis with cardiomyopathy', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['ITEM 1A. RISK FACTORS', 'FILING DATE: 2025-05-01', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867025000052/alny-20250331.htm'], 'aliases': []}, {'name': 'AMVUTTRA', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR amyloidosis with cardiomyopathy', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Launch in additional countries during the remainder of 2025'], 'references': ['SEC Filing', 'March 31, 2025'], 'aliases': []}, {'name': 'Leqvio', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC Filing', 'March 31, 2025'], 'aliases': []}, {'name': 'Qfitlia', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC Filing', 'March 31, 2025'], 'aliases': []}, {'name': 'zilebesiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC Filing', 'March 31, 2025'], 'aliases': []}, {'name': 'ONPATTRO', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC Filing', 'March 31, 2025'], 'aliases': []}, {'name': 'GIVLAARI', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC Filing', 'March 31, 2025'], 'aliases': []}, {'name': 'OXLUMO', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC Filing', 'March 31, 2025'], 'aliases': []}, {'name': 'Leqvio', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing', 'December 2021', ''], 'aliases': []}, {'name': 'Qfitlia', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing', '', ''], 'aliases': []}, {'name': 'zilebesiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['SEC filing', '', ''], 'aliases': []}, {'name': 'mivelsiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': ['Ongoing Phase 2 development program'], 'upcoming_milestones': ["Full development and commercialization rights following Regeneron's opt-out"], 'references': ['SEC filing section 42', 'Filing date not specified', 'URL not available'], 'aliases': []}, {'name': 'zilebesiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': ["Phase 3 clinical trial initiation contingent on Roche's decision"], 'upcoming_milestones': ['Potential Phase 3 initiation milestone payment from Roche'], 'references': ['SEC filing section 42', 'Filing date not specified', 'URL not available'], 'aliases': []}, {'name': 'inclisiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Termination rights granted to Novartis with prior notice'], 'references': ['SEC filing section 42', 'Filing date not specified', 'URL not available'], 'aliases': []}, {'name': 'vutrisiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['NDA submission amendment due to third-party facility inspection'], 'references': ['SEC filing section 42', 'Filing date not specified', 'URL not available'], 'aliases': []}, {'name': 'AMVUTTRA', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR amyloidosis with cardiomyopathy', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'nucresiran', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR amyloidosis with cardiomyopathy', 'preclinical_data': [], 'clinical_trials': ['Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Patient enrollment for Phase 3 trial', 'Readouts and regulatory events dependent on enrollment'], 'references': [], 'aliases': ['formerly ALN-TTRsc04']}, {'name': 'mivelsiran', 'mechanism_of_action': '', 'target': '', 'indication': 'Alzheimer’s Disease', 'preclinical_data': [], 'clinical_trials': ['Phase 1 trial, partial clinical hold in the United States, results not specified'], 'upcoming_milestones': ['Potential impact of partial clinical hold on development plans'], 'references': [], 'aliases': []}, {'name': 'AMVUTTRA', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR-CM', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Expansion of indication approval outside the U.S.'], 'references': ['SEC filing', '2025'], 'aliases': []}, {'name': 'patisiran', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR amyloidosis with cardiomyopathy', 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 clinical trial', 'Patients with ATTR amyloidosis with cardiomyopathy', 'Results reported positive, but FDA issued a CRL in October 2023'], 'upcoming_milestones': [], 'references': ['SEC filing', '2023'], 'aliases': []}, {'name': 'inclisiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': ['NDA resubmission to the FDA filed in July 2021', 'FDA approved Leqvio in December 2021'], 'upcoming_milestones': [], 'references': ['SEC filing', '2021'], 'aliases': ['Leqvio']}, {'name': 'patisiran', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR amyloidosis with cardiomyopathy', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'vutrisiran', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR amyloidosis with cardiomyopathy', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'AMVUTTRA', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'AMVUTTRA', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR amyloidosis with cardiomyopathy', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'ONPATTRO', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'GIVLAARI', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'OXLUMO', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'vutrisiran', 'mechanism_of_action': '', 'target': '', 'indication': 'Stargardt Disease', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'Qfitlia', 'mechanism_of_action': '', 'target': '', 'indication': 'hemophilia', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'zilebesiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'fitusiran', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'AMVUTTRA', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'ONPATTRO', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'GIVLAARI', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'OXLUMO', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'AMVUTTRA', 'mechanism_of_action': 'RNAi therapeutic', 'target': '', 'indication': 'ATTR amyloidosis', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'AMVUTTRA', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR amyloidosis with cardiomyopathy', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'WAINUA', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR amyloidosis with cardiomyopathy', 'preclinical_data': [], 'clinical_trials': ['Phase 3'], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, {'name': 'nexiguran ziclumeran', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR amyloidosis with cardiomyopathy', 'preclinical_data': [], 'clinical_trials': ['Phase 3'], 'upcoming_milestones': [], 'references': [], 'aliases': ['formerly NTLA-2001']}, {'name': 'ALN-2220', 'mechanism_of_action': '', 'target': '', 'indication': 'ATTR amyloidosis with cardiomyopathy', 'preclinical_data': [], 'clinical_trials': ['Phase 3'], 'upcoming_milestones': [], 'references': [], 'aliases': ['formerly NI006']}, {'name': 'coramitug', 'mechanism_of_action': '', 'target': '', 'indication': '', 'preclinical_data': [], 'clinical_trials': ['Phase 2'], 'upcoming_milestones': [], 'references': [], 'aliases': ['NNC-6019-0001']}, {'name': 'ATO-02', 'mechanism_of_action': '', 'target': '', 'indication': 'hATTR amyloidosis with polyneuropathy', 'preclinical_data': [], 'clinical_trials': ['Phase 2'], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'RIVFLOZA', 'mechanism_of_action': '', 'target': '', 'indication': 'PH1', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'OXLUMO', 'mechanism_of_action': 'RNAi therapeutic', 'target': '', 'indication': 'PH1', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, {'name': 'TEGSEDI', 'mechanism_of_action': 'antisense drug', 'target': '', 'indication': 'hATTR amyloidosis with polyneuropathy', 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}]}
[2025-05-13T17:07:15.138+0000] {logging_mixin.py:190} INFO - Drug facts collected so far: {'drugs': {'AMVUTTRA': {'indication': ['ATTR amyloidosis', 'ATTR amyloidosis with cardiomyopathy', 'ATTR-CM'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['Expansion of indication approval outside the U.S.', 'Launch in additional countries during the remainder of 2025'], 'references': ['2025', 'FILING DATE: 2025-05-01', 'ITEM 1A. RISK FACTORS', 'March 31, 2025', 'SEC Filing', 'SEC filing', 'https://www.sec.gov/Archives/edgar/data/1178670/000117867025000052/alny-20250331.htm'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic']}, 'Leqvio': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['', 'December 2021', 'March 31, 2025', 'SEC Filing', 'SEC filing'], 'aliases': []}, 'Qfitlia': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['', 'March 31, 2025', 'SEC Filing', 'SEC filing'], 'aliases': [], 'indication': ['hemophilia']}, 'zilebesiran': {'preclinical_data': [], 'clinical_trials': ["Phase 3 clinical trial initiation contingent on Roche's decision"], 'upcoming_milestones': ['Potential Phase 3 initiation milestone payment from Roche'], 'references': ['', 'Filing date not specified', 'March 31, 2025', 'SEC Filing', 'SEC filing', 'SEC filing section 42', 'URL not available'], 'aliases': []}, 'ONPATTRO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['March 31, 2025', 'SEC Filing'], 'aliases': []}, 'GIVLAARI': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['March 31, 2025', 'SEC Filing'], 'aliases': []}, 'OXLUMO': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': ['March 31, 2025', 'SEC Filing'], 'aliases': [], 'mechanism_of_action': ['RNAi therapeutic'], 'indication': ['PH1']}, 'mivelsiran': {'preclinical_data': [], 'clinical_trials': ['Ongoing Phase 2 development program', 'Phase 1 trial, partial clinical hold in the United States, results not specified'], 'upcoming_milestones': ["Full development and commercialization rights following Regeneron's opt-out", 'Potential impact of partial clinical hold on development plans'], 'references': ['Filing date not specified', 'SEC filing section 42', 'URL not available'], 'aliases': [], 'indication': ['Alzheimer’s Disease']}, 'inclisiran': {'preclinical_data': [], 'clinical_trials': ['FDA approved Leqvio in December 2021', 'NDA resubmission to the FDA filed in July 2021'], 'upcoming_milestones': ['Termination rights granted to Novartis with prior notice'], 'references': ['2021', 'Filing date not specified', 'SEC filing', 'SEC filing section 42', 'URL not available'], 'aliases': ['Leqvio']}, 'vutrisiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': ['NDA submission amendment due to third-party facility inspection'], 'references': ['Filing date not specified', 'SEC filing section 42', 'URL not available'], 'aliases': [], 'indication': ['ATTR amyloidosis with cardiomyopathy', 'Stargardt Disease']}, 'nucresiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Phase 3 trial, size not specified, endpoints not specified, dates not specified, results not specified'], 'upcoming_milestones': ['Patient enrollment for Phase 3 trial', 'Readouts and regulatory events dependent on enrollment'], 'references': [], 'aliases': ['formerly ALN-TTRsc04']}, 'patisiran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['APOLLO-B Phase 3 clinical trial', 'Patients with ATTR amyloidosis with cardiomyopathy', 'Results reported positive, but FDA issued a CRL in October 2023'], 'upcoming_milestones': [], 'references': ['2023', 'SEC filing'], 'aliases': []}, 'fitusiran': {'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'WAINUA': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Phase 3'], 'upcoming_milestones': [], 'references': [], 'aliases': ['eplontersen']}, 'nexiguran ziclumeran': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Phase 3'], 'upcoming_milestones': [], 'references': [], 'aliases': ['formerly NTLA-2001']}, 'ALN-2220': {'indication': ['ATTR amyloidosis with cardiomyopathy'], 'preclinical_data': [], 'clinical_trials': ['Phase 3'], 'upcoming_milestones': [], 'references': [], 'aliases': ['formerly NI006']}, 'coramitug': {'preclinical_data': [], 'clinical_trials': ['Phase 2'], 'upcoming_milestones': [], 'references': [], 'aliases': ['NNC-6019-0001']}, 'ATO-02': {'indication': ['hATTR amyloidosis with polyneuropathy'], 'preclinical_data': [], 'clinical_trials': ['Phase 2'], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'RIVFLOZA': {'indication': ['PH1'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}, 'TEGSEDI': {'mechanism_of_action': ['antisense drug'], 'indication': ['hATTR amyloidosis with polyneuropathy'], 'preclinical_data': [], 'clinical_trials': [], 'upcoming_milestones': [], 'references': [], 'aliases': []}}}
[2025-05-13T17:07:15.183+0000] {logging_mixin.py:190} INFO - Schema validation passed.
[2025-05-13T17:07:15.753+0000] {logging_mixin.py:190} INFO - Deleted output_dir: sec_data/ALNY
[2025-05-13T17:07:15.762+0000] {python.py:240} INFO - Done. Returned value was: None
[2025-05-13T17:07:15.841+0000] {taskinstance.py:340} INFO - ::group::Post task execution logs
[2025-05-13T17:07:15.844+0000] {taskinstance.py:352} INFO - Marking task as SUCCESS. dag_id=sec_filing_scheduler, task_id=process_alny, run_id=manual__2025-05-13T17:05:43.854334+00:00, execution_date=20250513T170543, start_date=20250513T170558, end_date=20250513T170715
[2025-05-13T17:07:16.046+0000] {local_task_job_runner.py:266} INFO - Task exited with return code 0
[2025-05-13T17:07:16.117+0000] {taskinstance.py:3895} INFO - 0 downstream tasks scheduled from follow-on schedule check
[2025-05-13T17:07:16.122+0000] {local_task_job_runner.py:245} INFO - ::endgroup::
